CCIA
FPRX

Campbell & Co Investment Adviser’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,200
Closed -$361K – 658
2020
Q4 		$361K Buy
+21,200
New +$266K 0.22% 170
2019
Q3 		– Sell
-24,066
Closed -$145K – 826
2019
Q2 		$145K Buy
24,066
+12,146
+102% +$116K 0.07% 488
2019
Q1 		$160K Buy
+11,920
New +$136K 0.08% 473

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Campbell & Co Investment Adviser's FPRX Position: Q1 2021 in Review

Campbell & Co Investment Adviser sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 21,200 shares — an estimated $361K sold.

Campbell & Co Investment Adviser first reported a position in FPRX in Q1 2019 and held it in 3 quarters. The position peaked at $361K in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Campbell & Co Investment Adviser reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 21,200 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $361K.
  • Campbell & Co Investment Adviser first reported a position in Five Prime Therapeutics, Inc. in Q1 2019 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Five Prime Therapeutics, Inc. position peaked at $361K in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2021, filed 14 May 2021.